Dipeptidyl Peptidase-4 Inhibitors For The Treatment Of Type 2 Diabetes Mellitus
Share This:
                           

About The Author

Dayong Shi is a pharmaceutics researcher associated with the Chinese Academy of Sciences | CAS · Institute of Oceanology.

 

                       

Dipeptidyl Peptidase-4 Inhibitors For The Treatment Of Type 2 Diabetes Mellitus

Diabetes is a fast-growing, global chronic metabolic disorder. According to the newest data from the International Diabetes Federation (IDF), about 425 million adults had diabetes in 2017, and the number is expected to rise to 700 million in 2045. DPP-4 (CD26, EC 3.4.14.5) is a serine peptidase expressed as a 220 kDa homodimeric type II transmembrane glycoprotein on the surface of various cell types. The mechanisms for the glucose-lowering action of DPP-4 inhibitors include GLP-1-dependent and GLP-1-independent mechanisms. Apart from...

Read more